Onconetix is a small, commercial-stage diagnostics company focused on prostate cancer detection. Its sole active product is Proclarix, a blood-based in vitro diagnostic test that helps physicians decide whether a patient with an elevated PSA level needs a prostate biopsy. Proclarix measures two protein biomarkers in a standard blood sample using ELISA immunoassay technology — equipment already found in most diagnostic labs — and combines these values with PSA levels, patient age, and prostate volume in a proprietary algorithm to produce a risk score. Clinical studies suggest Proclarix can reduce unnecessary biopsies by roughly 43% while maintaining high sensitivity for clinically significant cancer. Proclarix is CE-marked and sold in Europe, where Onconetix targets urologists and diagnostic labs in Switzerland, Germany, Italy, and the UK. In the US, Onconetix has licensed Proclarix exclusively to LabCorp, which is responsible for commercializing it as a lab-developed test. Onconetix's revenue model is straightforward: kit sales to labs, plus royalties and milestones from LabCorp. The key constraints on growth are reimbursement — Proclarix is not yet reimbursed in Europe, so patients pay out of pocket — and lab and physician adoption. The company outsources manufacturing to a contract manufacturer in Germany. Onconetix also earns a small royalty from Immunovia, which licenses Proteomedix biomarker technology for a pancreatic cancer diagnostic. In February 2026, Onconetix entered into an agreement to acquire Realbotix, an AI robotics company, in a deal that would effectively make Realbotix the surviving operating business, representing a potential full pivot away from diagnostics.